Dendritic cells (DC) are antigen-presenting cells whose immunobiology has been proven to be central to the function of the immune system. Further understanding of these cells is leading the way to the manipulation of the immune system as a tool to cure and prevent a vast array of diseases including cancers. These cells have been used in trials as vaccine adjuvants in therapies that aim to break the body's tolerance to the tumor. From the first 1000 DC vaccinees in 2003 there has been a breadth of information on safety that is paving the way to the study of the efficiency of these therapies. This review aims to explore recent updates to the current literature on DC vaccine therapies in clinical trials and analyze their future. At this crossroads is where intricacies of the technique are being revised to explore the most efficient and effective parameters for the enhancement of DC adjuvant therapies.